Zhaoke Ophthalmology Limited reported that it repurchased 1.29 million ordinary shares on the Hong Kong Stock Exchange between 11 and 23 June 2026 for cancellation. The cumulative buy-backs equal 0.23% of the company’s 548.75 million issued shares outstanding.

Key figures • Repurchase volume: 1,285,500 shares • Share price range: HKD 2.54 – HKD 2.83 per share • Estimated total consideration: about HKD 3.49 million, based on disclosed per-share prices • Latest daily transaction (23 June): 121,500 shares at up to HKD 2.5647, costing HKD 0.31 million • Remaining authority: After the transactions, 2.34% of the 54.87 million-share buy-back mandate approved on 15 May 2026 has been used.

Capital structure • Opening and closing issued share count (excluding treasury shares): 548,749,012 • No new shares were issued, and no treasury shares were held as at 23 June 2026. • All repurchased shares have been earmarked for cancellation and will reduce the share count once formal cancellation is completed.

Regulatory timeline • The company is subject to a 30-day moratorium on issuing new shares or transferring treasury shares following the 23 June buy-back, expiring on 23 July 2026. • Management confirmed that all repurchases complied with Hong Kong Main Board Listing Rule 10.06 and related regulations.

Implications The recent activities signal Zhaoke Ophthalmology’s continued use of its share repurchase authority, reflecting an emphasis on shareholder value while maintaining its issued share base unchanged until the cancellations take effect.